All News

elderly hands

A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology

Jiha Lee, MD

A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional structures.

Read Article
manpower.cliff.shortage

Rheumatology Shortage Cliff in Australia & USA

Jack Cush, MD

Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.

Read Article
RA,polyarticular,black,rheumatoid

ACPA and the Transition from Arthralgia to Rheumatoid Arthritis

MedPage Today

Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.

Read Article
PsA.Xray_.Erosion.Cup_.jpg

Guselkumab gets FDA Nod for X-ray Protection

Jack Cush, MD

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). 

Read Article
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article
TOGETHER PsA trial IXE+TIRZEPATIDE TZP vs. IXE alone RCT Obese or Overweight PsA IR to <3 bioDMARDs Primary endpoint ≥10% weight & ACR50 wk 36 31.7% IXE+TZP vs. 0.8% for IXE alone ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02) No clear difference by gender/age/BMI/previous DMARDs https://t.co/lFbeb85b9Y

Links:

https://twitter.com/ ( View Tweet)
You CAN identify #ILD in #rheumatic #diseases 🔜early With a brief #questionnaire Ask re ➡️dry cough ➡️dyspnea ➡️smoking Not sensitive but high #specificity Is it too late? Maybe chest #auscultation at the #bases would be better? 🤷 #EULAR2026 ABST#POS0433 @RheumNow https://t.co/JA3k1cSHt7

Links:

Janet Pope Janetbirdope ( View Tweet)
In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460

Jiha Lee JihaRheum ( View Tweet)

Does #Rx w #immunesuppression w #antifibrotic Help #SARD-ILD? YES. N=40 SARD-ILD, 1/2 w UIP pattern Use of #IS w #antifibrotic pt group had better survival Small N and ?channeling bias But interesting results TAke home : Use IS + antifibrotic #EULAR2026 #POS0530 @RheumNow https://t.co/tfxVVw27jJ

Links:

Janet Pope Janetbirdope ( View Tweet)
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE. -Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease: -No flare in INEB group; 6% flare in PBO-INEB -10.9% serious infections -1 pt discontinued due to low IgG Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs. #EULAR2026 @RheumNow https://t.co/JmTSC1uaph

Links:

sheila RHEUMarampa ( View Tweet)
#Vaccination in Rheum 📍Hold MTX 1-2wks post vax 📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals. THM: Assess vax need at dx, vax w/o delay #EULAR2026 @RheumNow https://t.co/6ptl8gyBLR

Links:

sheila RHEUMarampa ( View Tweet)
Integrating D2T into T2T Practices in RA Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and https://t.co/buCXeK2jNS
Dr. John Cush RheumNow ( View Tweet)
“Common sense in matters medical is rare, and is usually in inverse ratio to the degree of education.” – Sir William Osler

Dr. John Cush RheumNow ( View Tweet)

Which of the following is NOT a complication of Gout?

Dr. John Cush RheumNow ( View Tweet)

Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/a9RSo9PxHS https://t.co/nIOR9AUjQs

Links:

Dr. John Cush RheumNow ( View Tweet)
EGPA https://t.co/zlquehIZQ6

Links:

Rheumatology update aabdogafar ( View Tweet)
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/YIupsBank5

Links:

Dr. John Cush RheumNow ( View Tweet)
Adverse drug events (ADEs) studied in autoimmune rheum Dz (ARDs). In 10,578 ARD pts 30% had 1+ ADE, highest in SSc (36%). Polypharmacy (57.3% minor, 39.4% major) contrib to increasing ADEs. ADEs were more from Sx Rx (antacids, Tylenol, psychotropics) than DMARDs. https://t.co/BOAfU1DyIN
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×